Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

Slides:

Advertisements

Similar presentations

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Advertisements

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

From: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study Ann Intern Med. 2004;140(2):85-93.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated platelet aggregation. Acalabrutinib and ibrutinib therapy cause dysfunctional GPVI-mediated.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Alternate designs for conduct and analysis of phase I cancer trials

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study by Pier M. Mannucci,

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

by Timothy P. Hughes, and David M. Ross

Finding a diamond in the (mouse is) rough

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Nataliya Melnyk, and Jonathan Harrison

Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas by Yoshiyasu Aoki, Giovanna Tosato, Yoshihiro Nambu, Aikichi.

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

Genetic sequence analysis of inherited bleeding diseases

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Setting the table for macrophages

by Alexander Röth, Andreas Hüttmann, Russell P

Successful Treatment of Iron Overload by Phlebotomies in a Patient With Severe Congenital Dyserythropoietic Anemia Type II by W.K. Hofmann, J.P. Kaltwasser,

Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients.

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

by Sabah Sallah, and Jim Y. Wan

by Karl-Georg Fischer, Barbara Deschler, and Michael Lübbert

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Primary testicular lymphoma

ROCK and Rho(ll) in bone marrow

Blocking VWF platelet binding to treat TTP

Has MRD monitoring superseded other prognostic factors in adult ALL?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Anergy: the CLL cell limbo

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Radiology assessment of pulmonary amyloidosis

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Piecewise-Defined Function

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Plasma biomarker concentrations between study groups.

by Giovanni Palladini, and Giampaolo Merlini

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

by Wendy Lim, Sara K. Vesely, and James N. George

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Mean plasma concentrations of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis (duration depicted by box.

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Rituximab immunotherapy: it’s getting personal

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects by Naoki Uchida, Takehiko Sambe, Koichiro.

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Initial treatment of CLL: integrating biology and functional status

Diagnoses in patients with TA-GVHD.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients by Elena.

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis by Duncan B. Richards, Louise M. Cookson,

A change in either volume of distribution or clearance has differing effects on the concentration-time profile. A change in either volume of distribution.

Balancing bleeding in brain metastases

Cold agglutinin disease

Presentation transcript:

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell, Anja Drebes, Philip N. Hawkins, and Ashutosh D. Wechalekar Blood Volume 123(18):2899-2900 May 1, 2014 ©2014 by American Society of Hematology

The graph demonstrates FX levels post infusion of a single dose of 40 IU/kg of high-purity FX concentrate in 2 patients with AL amyloidosis with acquired FX deficiency. The graph demonstrates FX levels post infusion of a single dose of 40 IU/kg of high-purity FX concentrate in 2 patients with AL amyloidosis with acquired FX deficiency. Patient 1 (line with squares) and patient 2 (line with triangles) compared with a reference line constructed from FX levels of 3 patients with hereditary FX deficiency reported by Alvarez et al9 given the same concentrate at a dose of 25 IU/kg (line with circles). Shameem Mahmood et al. Blood 2014;123:2899-2900 ©2014 by American Society of Hematology